TORONTO–(BUSINESS WIRE)–Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the appointment of Antoinette Paone as Chief Development Officer (“CDO”) and Head of Regulatory Affairs. Ms. Paone brings extensive experience leading regulatory strategy from clinical development through approval, including her work on Kalydeco and Orkambi at.
This excerpt is quoted from the original release. Read the full announcement on Business Wire.
Brief Summary
Satellos Bioscience Inc. has announced the appointment of Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs. With her extensive experience in regulatory strategy, Ms. Paone is expected to lead the company’s efforts in developing innovative therapies for degenerative muscle diseases.
- 100% commitment to improving patient outcomes.
- Expertise in navigating regulatory challenges.
- Track record of successful drug approvals.
- Strategic planning for clinical trials.
- Focus on Kalydeco and Orkambi experience.
Why it matters: The addition of Ms. Paone signifies Satellos’ dedication to advancing its drug development pipeline and leveraging her expertise to maximize market opportunities.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by Business Wire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.